Company intelligence / Profile preview

IsoPlexis

Branford, Connecticut, United States

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Peer-reviewed evidence shows IsoPlexis’ instruments predict CAR-T cell therapy efficacy by single-cell cytokine profiling, validated in cancers like lymphoma; widely adopted in major pharma and cancer centers[5].

Therapeutic areas: HematologyOncologyInfectious DiseasesImmunology
Modalities: DevicePlatform technology for Immune cell analysisSingle-cell proteomics instrumentsBiologicCAR-T cell therapyVaccineSmall moleculeMonoclonal antibody drug programs
Industry: Protein Biomarker Diagnostics

Partnerships

Virtualitics (AI data analytics)collaborations with major pharma companies including 15 global pharmaceutical companies and nearly half of the NCI-designated comprehensive cancer centers in the USA

Beyond the preview

Go deeper on IsoPlexis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IsoPlexis.

Explore the full profile